![](https://webarchive.library.unt.edu/eot2008/20090115064023im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090115064023im_/http://www.cancer.gov/images/spacer.gif)
lestaurtinib An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090115064023im_/http://www.cancer.gov/images/spacer.gif)
Code names: | ![](https://webarchive.library.unt.edu/eot2008/20090115064023im_/http://www.cancer.gov/images/spacer.gif) | CEP-701 KT-5555 SPM-924 | | ![](https://webarchive.library.unt.edu/eot2008/20090115064023im_/http://www.cancer.gov/images/spacer.gif) | Chemical structure name: | ![](https://webarchive.library.unt.edu/eot2008/20090115064023im_/http://www.cancer.gov/images/spacer.gif) | 9,12-epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- | | ![](https://webarchive.library.unt.edu/eot2008/20090115064023im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090115064023im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115064023im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115064023im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090115064023im_/http://www.cancer.gov/images/spacer.gif) |